ClinicalTrials.gg
Status unknownNCT01729663Updated Sep 2, 2015

Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients

A Phase 2/3 interventional study of CSF470 vaccine, BCG, Molgramostim and interferon alpha 2b in Cutaneous Melanoma, sponsored by Laboratorio Pablo Cassará S.R.L.. Status unknown at 1 site in Argentina. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-09-02.

Sponsored by Laboratorio Pablo Cassará S.R.L. · Phase 2/3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2015), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 50 studies in Melanoma with a site in Argentina — 3 open to participants now, 12 under way, 8 of them phase 3. Melanoma · Argentina.

Planned enrollment
41st of 47
108 · median 498
Started
2009
the only one that year
Phase 2/3
2 of 50
none open now
Registered
21st of 50
by date

Among the 50 studies in Melanoma with a site in Argentina, this one is the 41st largest by planned enrollment of the 47 interventional ones that give a count, is the only one that started in 2009, is one of 2 in phase 2/3, and was the 21st registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

3 of the 50 studies in Melanoma with a site in Argentina are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Melanoma with a site in Argentina, or all of them as a file.
02

Study summary

Randomized, open, Phase II-III study, comparative between treatment with CSF-470 vaccine , allogeneic, irradiated with BCG and molgramostin (rHuGM-CSF) as adjuvants and interferon alfa 2b (IFN-alpha2b) treatment , in stages IIB, IIC o III (AJCC) post-surgery cutaneous melanoma patients. This study has been approved by ANMAT ( Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT)), number 1556/2011 (www.anmat.gov.ar).

The study Institution is Instituto Médico Especializado Alexander Fleming, Ciudad Autónoma de Buenos Aires, Argentina. The Sponsor is Laboratory Pablo Cassará (LPC, S.R.L.).

Study population include a total of 108 patients (72 patients will receive CSF470 vaccine and 36 patients will receive alpha IFN-alpha 2b) for a total of 24 months.

CSF-470 treatment will consist of four vaccine doses id injection (three weeks apart), then one dose every two months for the first year and them every three months for the second year.

Each vaccine consist of a mixture of 17,6.106 melanoma cells, from four melanoma cell lines, not genetically modified and lethally irradiated. As adjuvant BCG (120 µg prot) the first day and rHuGM-CSF (Molgramostim, 400 µg, fractionated in four days doses) will be used.

IFN-alpha 2b treatment will consist of s.c. injection of 10 million units (MU) (5 t/w ) for four weeks and then 5 MU (3t/w) for 23 months.

Both treatments will also compare quality of life (QOL) and study a possible correlation in the CSF470 vaccine arm between the induced immune response and clinical outcome

03

Conditions studied

  • Cutaneous Melanoma

Browse trials for

Keywords

  • melanoma
  • irradiated-allogeneic cells
  • therapeutic vaccine
  • Interferon alpha 2-b
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed cutaneous melanoma stages IIB, IIC or III (AJCC)
  • patients non-detectable disease (NED) after surgery as asserted by CAT scans. Melanoma pts with unknown primary tumor site could be included in the study
  • > 6 months
  • performance status () 0 or 1
  • Time post surgery not more than 4 months
  • no chemotherapy, radiotherapy or any biological treatments prior to this study.
  • patients must have CATscans of brain, thorax, abdomen and pelvis in the 60 previous days to trial enrolling
  • To have laboratory studies (no more than 15 days before entering the study)
  • laboratory eligibility criteria include: hematocrit: ≥35 ( > 10,5 gr %); WBC count > 3500/mm3, > 100.000/mm3, total and direct , serum oxalacetic transaminase and glutamic pyruvic transaminase \< 1.5 fold the upper normal value; LDH ≤ 450 mU/ml
  • negative serology for , anti- and
  • serum creatinine \< 2.0 mg %
  • all patients must give written before inclusion in the Study.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast-feeding women
  • Diabetes (Type I or II)
  • Antecedents of psychiatric diseases
  • Evidence of active infections
  • Antecedents of viral or hepatitis
  • Previous autoimmune diseases
  • Morbid Obesity, defined as CMI (Corporal mass index)>37 kg/m2 in women and >40 kg/m2 in men.
  • Other diseases that require treatment with regular corticoids or non anti-inflammatory drugs
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Active comparator
    Interferon alpha 2 b

    Interferon alpha 2b treatment will consist of s.c. injection of 10 MU (5 t/w) for four weeks and then 5 MU (3t/w) for 23 months.

    Drug: interferon alpha 2b

  • Experimental
    CSF470 vaccine, BCG, Molgramostim

    CSF470 vaccine, BCG, Molgramostim CSF-470 treatment will consist of four vaccine doses id injection (three weeks apart), then one dose every two months for the first year and them every three months for the second year. Each vaccine consist of a mixture of 17,6.106 melanoma cells , from four melanoma cell lines, not genetically modified and lethally irradiated. As adjuvant BCG (120 µg prot) the first day and rhGM-CSF (Molgramostim 400 µg, fractionated in four days doses) will be used.

    Biological: CSF470 vaccine, BCG, Molgramostim

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy

    OS, DFS, Partial or total remission (PR or CR)

    Time frame: two years

  2. security

    measured according to the NCI-Common Toxicity Criteria

    Time frame: two years

Secondary outcomes

  1. Quality of Life

    QOL:evaluated with EORTC QLQ-C30 questionnaire; ECOG Performance status

    Time frame: two years

  2. Induction of immune responses

    Induction of immune responses associated to different vaccine doses for 2 years (Trial duration) \]Cellular immunity (DTH) - Humoral immunity

    Time frame: two years

07

Study locations

1 of 1 sites recruiting
  • Instituto Médico Alexander Fleming
    Buenos Aires, Capital Federal 1426, Argentina
    Recruiting
    • José Mordoh, MD, PhD · Contactjmordoh@leloir.org.ar · 44-11-6323-2900
    • José Mordoh, MD, PhD · Principal investigator
    • María M Barrio, PhD · Sub investigator
08

References and documents

Publications

  • Aris M, Bravo AI, Pampena MB, Blanco PA, Carri I, Koile D, Yankilevich P, Levy EM, Barrio MM, Mordoh J. Changes in the TCRbeta Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report. Front Immunol. 2018 May 3;9:955. doi: 10.3389/fimmu.2018.00955. eCollection 2018. PubMed 29774030 ↗
  • Mordoh J, Pampena MB, Aris M, Blanco PA, Lombardo M, von Euw EM, Mac Keon S, Yepez Crow M, Bravo AI, O'Connor JM, Orlando AG, Ramello F, Levy EM, Barrio MM. Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study. Front Immunol. 2017 May 31;8:625. doi: 10.3389/fimmu.2017.00625. eCollection 2017. PubMed 28620382 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009 and a primary completion of Dec 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2012
First posted
Nov 20, 2012
Start
Apr 2009
Primary completionEst.
Dec 2018
Last update
Sep 2, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01729663
Lead sponsor
Laboratorio Pablo Cassará S.R.L.
Collaborators
Fundacion Sales, National Agency for Scientific and Technological Promotion, Argentina, Fundacion Cancer FUCA, National Council of Scientific and Technical Research, Argentina, Instituto Nacional del Cáncer, Argentina
Responsible party
José Mordoh (MD, PhD, Laboratorio Pablo Cassará S.R.L.) — Principal investigator
First posted
Nov 20, 2012
Start date
Apr 2009
Primary completion
Dec 2018 (estimated)
Last update
Sep 2, 2015

Study contacts

José Mordoh, MD, PhD
Contact
jmordoh@alexanderfleming.org
54-11-6323-2900 ext. 2205
María M Barrio, PhD
Contact
barrio.marcela@gmail.com
54-11-6323-2900 ext. 1110
José Mordoh, MD, PhD
principal investigator · Instituto Médico Alexander Fleming

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: BCG Vaccine · Molgramostim

Start the discussion